ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Madrigal Pharmaceuticals, Inc. (MDGL) shows an Average True Range (ATR) of 15.96 and an Enterprise Value of 4.31B. Its average trading volume over the past 3 months is 376.08K, indicating liquidity. These fundamental metrics provide insight into MDGL's underlying financial health and market activity.
Madrigal Pharmaceuticals, Inc. (MDGL) technical indicators as of October 2, 2025: the SMA 20 is 2.82%, SMA 50 at 13.83%, and SMA 200 at 34.93%. The RSI 14 value is 60.87, suggesting its current momentum. These technical analysis signals help assess MDGL's price trends and potential future movements.
Madrigal Pharmaceuticals, Inc. (MDGL) stock performance overview as of October 2, 2025: The 52-week high is $463.63 (currently -3.02% below), and the 52-week low is $200.63 (currently 124.11% above). Over the past year, MDGL's performance is 111.67%, compared to the S&P 500's 15.68% change.
According to market data, Madrigal Pharmaceuticals, Inc. (MDGL) stock's recent performance metrics show that over the last month, MDGL is 3.3%, with a Year-to-Date (YTD) performance of 45.72%. Over the past year, the stock has seen a 111.67% change. These figures summarize MDGL's price movements across various periods, reflecting its historical returns.
According to current financial data, MDGL stock's P/E (TTM) ratio is -35.73, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for MDGL, including P/S (19.61), P/B (14.47), and P/FCF (-32.78), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.